Thyrocare Technologies Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Thyrocare Technologies Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Thyrocare Technologies Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news and updates on Thyrocare Technologies Ltd. from all sources in a single place.

Thyrocare Technologies Ltd.

29 Apr 2025

920.60

0.79%

Earnings Call

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Please find attached herewith Transcript for conference call held on April 23, 2022.

pdf

Thyrocare Technologies Ltd.

25 Apr 2025

920.60

0.79%

This smallcap stock zooms 32% in 1 week, nears 52-week high. Do you own?

Business Standard

Share price of Thyrocare Technologies has moved higher by 11 per cent to 938.65 on the BSE in Friday's intra-day trade and recovered 13 per cent from its intra-day low of 830.90.

Thyrocare Technologi.. has an average target of 1000.00 from 1 broker.

Thyrocare Technologies Ltd.

24 Apr 2025

920.60

0.79%

Company Update

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached herewith Newspaper Advertisements of Audited Financial results for Quarter and year ended March 31, 2025.

pdf

Thyrocare Technologies Ltd.

24 Apr 2025

920.60

0.79%

This smallcap healthcare company's stock rallied 19% after posting Q4 nos

Business Standard

Thyrocare Technologies share price: In Q4, the company's consolidated net profit including exceptional items stood at 21.3 crore as compared to 17.2 crore a year ago

Thyrocare Technologies Ltd. is trading above all available SMAs

Thyrocare Technologies Shares Hit Eight-Month High After Rise In Q4 Net Profit

NDTV Profit | 24 Apr 2025

Thyrocare Technologies Ltd.

24 Apr 2025

920.60

0.79%

Volume spurt maintained, margin outlook improving

Buy: Thyrocare Technologies Ltd.

Target

ICICI Securities Limited

Thyrocare Technologies’ (Thyrocare) outperformance in Q4FY25 was driven by surge in volumes (up 15%) and realisation improvement, partially offset by higher ESOP cost.